Table S1.

Stratified analysis on MKI67 expression level with outcomes in HBV-related HCC patients in Zhongshan cohort

Variables		OS		p-value	RFS		p-value	5-year RFS		p-value
		HR	95% CI		HR	95% CI		HR	95% CI
Gender	Male	1.53	0.97–2.43	0.071	1.30	0.89–1.91	0.176	1.57	1.07–2.31	0.021
	Female	2.21	0.53–9.25	0.279	2.11	0.59–7.50	0.249	2.19	0.61–7.84	0.227
Age	≤50 years	1.57	0.86–2.94	0.143	1.27	0.75–2.16	0.379	1.57	0.92–2.68	0.097
	>50 years	1.59	0.85–2.97	0.146	1.52	0.92–2.51	0.106	1.62	0.98–2.69	0.060
Cirrhosis	Yes	1.58	1.01–2.46	0.045	1.38	0.95–2.01	0.089	1.51	1.04–2.19	0.032
	None	1.64	0.10–26.35	0.726	1.07	0.18–6.40	0.943	2.78	0.46–16.92	0.267
Main tumor size	<5 cm	1.49	0.83–2.65	0.179	1.43	0.90–2.26	0.127	1.75	1.10–2.77	0.018
	≥5 cm	1.52	0.77–3.00	0.232	1.20	0.66–2.21	0.551	1.27	0.69–2.34	0.444
Multinodular	None	2.04	1.21–3.45	0.008	1.54	1.02–2.33	0.042	1.76	1.16–2.67	0.008
	Yes	0.71	0.31–1.61	0.408	0.83	0.39–1.80	0.642	1.06	0.49–2.30	0.879
Serum AFP	≤300 ng/mL	2.57	1.33–4.96	0.005	1.83	1.10–3.02	0.019	2.38	1.43–3.97	0.001
	>300 ng/mL	0.93	0.51–1.69	0.804	0.90	0.53–1.54	0.705	1.01	0.59–1.73	0.968
BCLC stage	0–A	1.77	1.01–3.10	0.048	1.38	0.89–2.13	0.155	1.73	1.11–2.68	0.015
	B–C	1.08	0.54–2.17	0.829	1.11	0.57–2.14	0.763	1.11	0.57–2.14	0.763

Notes: Bold items represent p<0.05.

Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HR, hazard ratio; OS, overall survival; RFS, recurrence-free survival.